Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None

PI Accessory Mutations: None

PR Other Mutations: K14R --- E33D --- N36I --- R57K --- H69K --- L89M ---

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

Mutation scoring: PR

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None

NNRTI Mutations: K103N ***

RT Other Mutations: K11T == . K20R == . V21I == . V25T == . V25S =

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

zidovudine (AZT)

stavudine (D4T)

didanosine (DDI)

emtricitabine (FTC)

lamivudine (3TC)

tenofovir (TDF)

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

Susceptible

High-Level Resistance

Susceptible

Susceptible

RT comments

NNRTI

K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

Other

Mutation scoring: RT

V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

	Rule	DOR ‡	EFV ÷	ETR ÷	NVP ≑	RPV	÷
	K103N	0	60	0	60	0	

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None INSTI Accessory Mutations: None

IN Other Mutations: K14R - S24SN - S24

Integrase Strand Transfer Inhibitors

bictegravir (BIC) Susceptible
cabotegravir (CAB) Susceptible
dolutegravir (DTG) Susceptible
elvitegravir (EVG) Susceptible
raltegravir (RAL) Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.